Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.45 |
| ▸ | AR | P10275 | 6/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | BCL2A1 | Q16548 | 4/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21029507 | 0.88 | PGR (0.45) | PGRAREPHX2S1PR1KCNJ1 | |
| SCHEMBL31498678 | 0.83 | AR (0.50) | PGRARTBK1 | |
| SCHEMBL22556937 | 0.82 | AR (0.58) | PGRAR | |
| SCHEMBL22565438 | 0.82 | AR (0.58) | PGRAR | |
| SCHEMBL19833654 | 0.82 | PGR (0.39) | PGRAREPHX2S1PR1KCNJ1 | |
| SCHEMBL19833661 | 0.82 | PGR (0.39) | PGRAREPHX2S1PR1KCNJ1 | |
| Hydrochloric Acid SCHEMBL31588028 | 0.82 | AR (0.49) | PGRARTBK1 | |
| Hydrochloric Acid SCHEMBL26113776 | 0.81 | AR (0.57) | PGRAR | |
| Hydrochloric Acid SCHEMBL26113781 | 0.81 | AR (0.57) | PGRAR | |
| SCHEMBL24267621 | 0.81 | PGR (0.43) | PGRARBCL2A1MPOS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025085738-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | VHL, BRCA1, TP53 | PGR 436/4885AR 338/4885EPHX2 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.